agilon health, inc. revised revenue guidance for the full year ending December 31, 2024. For the full year, the company now expects total revenues of $6,350 million to $6,465 million compared to previous guidance of $6,350 million to $6,420 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5 USD | -2.53% | -8.42% | -60.16% |
Apr. 22 | Citigroup Starts agilon health With Neutral Rating, $6 Price Target | MT |
Mar. 06 | Barclays Initiates Agilon Health With Underweight Rating, Price Target is $5 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.16% | 2.06B | |
-21.25% | 2.91B | |
-20.94% | 2.67B | |
-25.10% | 323M | |
-4.99% | 211M | |
-47.38% | 172M | |
-27.37% | 123M |
- Stock Market
- Equities
- AGL Stock
- News agilon health, inc.
- Agilon health, inc. Revises Revenue Guidance for the Full Year Ending December 31, 2024